Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.
Anders CK, Woodcock MG, Van Swearingen AED, Moore DT, Sambade MJ, Laurie S, Robeson A, Kolupaev O, Cuaboy LA, Garrett AL, McKinnon K, Cowens K, Bortone D, Calhoun BC, Wilkinson AD, Carey L, Jolly T, Muss H, Reeder-Hayes K, Kaltman R, Jankowitz R, Gudena V, Olajide O, Perou C, Dees EC, Vincent BG, Serody JS.
Anders CK, et al. Among authors: calhoun bc.
J Immunother Cancer. 2022 Feb;10(2):e003427. doi: 10.1136/jitc-2021-003427.
J Immunother Cancer. 2022.
PMID: 35121644
Free PMC article.
Clinical Trial.